Carl N. Kraus - 17 Jan 2023 Form 4 Insider Report for Aceragen, Inc.

Role
Chief Medical Officer
Signature
/s/ Carl N. Kraus
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
$0
Form type
4
Filing time
19 Jan 2023, 20:46:11 UTC
Previous filing
30 Sep 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACGN Options (Right to Buy) Options Exercise +440,844 440,844 17 Jan 2023 Common Stock 440,844 $208.76 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.
F2 The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F3 Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time.